Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Short term Debt (2024 - 2025)

Editas Medicine (EDIT) has disclosed Short term Debt for 2 consecutive years, with $5.0 million as the latest value for Q3 2025.

  • Quarterly Short term Debt changed N/A to $5.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Sep 2025, changed N/A year-over-year, with the annual reading at $5.0 million for FY2024, N/A changed from the prior year.
  • Short term Debt for Q3 2025 was $5.0 million at Editas Medicine, roughly flat from $5.0 million in the prior quarter.
  • The five-year high for Short term Debt was $5.0 million in Q4 2024, with the low at $5.0 million in Q4 2024.